"EC approves AstraZeneca’s Calquence combo to treat MCL" was originally created and published by Pharmaceutical Technology, a ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that a fixed-duration regimen of Calquence ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the European Union or EU has approved Calquence (acalabrutinib) in combination with bendamustine and rituximab ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...